Replies to post #153970 on Biotech Values

[Summer2762]

the response rate in triple negative BC was 19% compared to 0% for the investigator’s choice (IC) arm.

Is there a biological explanation why CDX-011 is active in triple-negative breast cancer? Has this been discussed? Or why this response rate did not translate to an OS advantage? Thanks.

About the exceptionally low p value for "Triple Negative and High GPNMB Expression": IMO, one of the major differences between "High GPNMB Expression" and "Triple Negative and High GPNMB Expression" KM graphs is just the removal of the 3 patients who lived 11.4, 12.5 and 21m because they were not triple negative. See the last 2 graphs in

http://www.celldextherapeutics.com/pdf/SABCS-2012-EMERGE-FINAL.pdf

This is a little bit difficult to realize because the graphs are on a different time scale. However, thanks to PDF (which scales nicely), if you zoom, you can match the patients in two graphs. This removal alone should explain the very low p value for the "Triple Negative and High GPNMB Expression" subset.

As for an explanation, it seems like something else (IC drug?) worked for these 3 patients and the removal of these patients from the last subset ensured that patients who lived exceptionally long are not included in the last graph (no competing therapies for TNBC)

[bladerunner1717]

Cantor Fitzgerald raises price target on CLDX to $13


Celldex Therapeutics (NASDAQ: CLDX) had its target price lifted by Cantor Fitzgerald from $9.00 to $13.00 in a report issued on Thursday. They currently have a buy rating on the stock.

A number of other firms have also recently commented on CLDX. Analysts at Oppenheimer raised their price target on shares of Celldex Therapeutics to $10.00 in a research note to investors on Monday, December 10th. Finally, analysts at Brean Murray reiterated a buy rating on shares of Celldex Therapeutics in a research note to investors on Monday, December 10th. They now have a $14.00 price target on the stock.

Shares of Celldex Therapeutics opened at 7.31 on Thursday. Celldex Therapeutics has a 52 week low of $3.07 and a 52 week high of $7.38. The stock’s 50-day moving average is currently $6.45. The company’s market cap is $453.0 million.

Bladerunner